XENCOR INC (XNCR)
US98401F1057 - Common Stock
XNCR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While XNCR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, XNCR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year XNCR has reported negative net income.
XNCR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XNCR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XNCR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of XNCR (-15.09%) is better than 86.50% of its industry peers.
XNCR has a Return On Equity of -21.78%. This is amongst the best in the industry. XNCR outperforms 86.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.09% | ||
| ROE | -21.78% | ||
| ROIC | N/A |
ROA(3y)-3.3%
ROA(5y)-3.15%
ROE(3y)-5.06%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XNCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XNCR has more shares outstanding
XNCR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XNCR is higher compared to a year ago.
2.2 Solvency
XNCR has an Altman-Z score of 2.54. This is not the best score and indicates that XNCR is in the grey zone with still only limited risk for bankruptcy at the moment.
XNCR has a better Altman-Z score (2.54) than 72.65% of its industry peers.
The Debt to FCF ratio of XNCR is 0.41, which is an excellent value as it means it would take XNCR, only 0.41 years of fcf income to pay off all of its debts.
XNCR has a better Debt to FCF ratio (0.41) than 97.09% of its industry peers.
XNCR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.02, XNCR perfoms like the industry average, outperforming 43.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.41 | ||
| Altman-Z | 2.54 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
XNCR has a Current Ratio of 7.08. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR has a better Current ratio (7.08) than 67.86% of its industry peers.
XNCR has a Quick Ratio of 7.08. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
XNCR has a Quick ratio of 7.08. This is in the better half of the industry: XNCR outperforms 67.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.08 | ||
| Quick Ratio | 7.08 |
3. Growth
3.1 Past
XNCR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.41%.
Looking at the last year, XNCR shows a very strong growth in Revenue. The Revenue has grown by 65.34%.
XNCR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.90% yearly.
EPS 1Y (TTM)6.41%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-8.82%
Revenue 1Y (TTM)65.34%
Revenue growth 3Y11.12%
Revenue growth 5Y32.9%
Revenue growth Q2Q-32.47%
3.2 Future
Based on estimates for the next years, XNCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
Based on estimates for the next years, XNCR will show a quite strong growth in Revenue. The Revenue will grow by 17.63% on average per year.
EPS Next Y-56.04%
EPS Next 2Y-17.49%
EPS Next 3Y3.82%
EPS Next 5Y13.7%
Revenue Next Year-51.94%
Revenue Next 2Y-14.4%
Revenue Next 3Y13%
Revenue Next 5Y17.63%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
XNCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XNCR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
96.58% of the companies in the same industry are more expensive than XNCR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.78 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.49%
EPS Next 3Y3.82%
5. Dividend
5.1 Amount
XNCR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
XENCOR INC
NASDAQ:XNCR (5/17/2024, 7:00:03 PM)
After market: 23.03 0 (0%)23.03
+0.57 (+2.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.09% | ||
| ROE | -21.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.08 | ||
| Quick Ratio | 7.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.41%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-56.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)65.34%
Revenue growth 3Y11.12%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y